Investment Landscape: Alzheimer's Disease

Investment Landscape: Alzheimer's Disease

Overview

Investment Landscape: Alzheimer's Disease covers the current R&D investment, [@clinicaltrialsgov]
clinical trial pipeline, and funding trends for Alzheimer's Disease research.

Last updated: 2026-03-17 19:20 PT

Clinical Trial Pipeline

Total Clinical Trials: 4910 Active Trials (Recruiting/Active): 1208

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 480 |
| PHASE1, PHASE2 | 113 |
| PHASE2 | 636 |
| PHASE2, PHASE3 | 68 |
| PHASE3 | 321 |
| PHASE4 | 168 |
| NA | 2082 |
| Not Applicable | 970 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 741 |
| ACTIVE_NOT_RECRUITING | 200 |
| NOT_YET_RECRUITING | 267 |
| COMPLETED | 2529 |
| TERMINATED | 324 |
| WITHDRAWN | 107 |

Top Therapeutic Approaches

• amyloid: 395 trials
• mitochondrial: 346 trials
• genetic: 226 trials
• [tau](/proteins/tau): 118 trials
• tauro: 118 trials
• metabolic: 111 trials
• neuroinflammation: 63 trials
• neurotransmitter: 53 trials

Investment Context

Alzheimer's disease represents the largest neurodegenerative investment area with 4,910 total clinical trials. The pipeline shows 480 Phase 1, 636 Phase 2, and 321 Phase 3 trials currently active. The high number of completed trials (2529) reflects decades of research investment, though the limited Phase 3 count indicates significant attrition in later-stage development.

Key Investment Themes

...

Investment Landscape: Alzheimer's Disease

Overview

Investment Landscape: Alzheimer's Disease covers the current R&D investment, [@clinicaltrialsgov]
clinical trial pipeline, and funding trends for Alzheimer's Disease research.

Last updated: 2026-03-17 19:20 PT

Clinical Trial Pipeline

Total Clinical Trials: 4910 Active Trials (Recruiting/Active): 1208

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 480 |
| PHASE1, PHASE2 | 113 |
| PHASE2 | 636 |
| PHASE2, PHASE3 | 68 |
| PHASE3 | 321 |
| PHASE4 | 168 |
| NA | 2082 |
| Not Applicable | 970 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 741 |
| ACTIVE_NOT_RECRUITING | 200 |
| NOT_YET_RECRUITING | 267 |
| COMPLETED | 2529 |
| TERMINATED | 324 |
| WITHDRAWN | 107 |

Top Therapeutic Approaches

• amyloid: 395 trials
• mitochondrial: 346 trials
• genetic: 226 trials
• [tau](/proteins/tau): 118 trials
• tauro: 118 trials
• metabolic: 111 trials
• neuroinflammation: 63 trials
• neurotransmitter: 53 trials

Investment Context

Alzheimer's disease represents the largest neurodegenerative investment area with 4,910 total clinical trials. The pipeline shows 480 Phase 1, 636 Phase 2, and 321 Phase 3 trials currently active. The high number of completed trials (2529) reflects decades of research investment, though the limited Phase 3 count indicates significant attrition in later-stage development.

Key Investment Themes

• Disease Modification: Majority of trials focus on disease-modifying therapies targeting [amyloid-beta](/proteins/amyloid-beta) and tau pathology
• Early Intervention: Growing emphasis on preclinical and prodromal AD trials
• Biomarker Development: Increased investment in diagnostic and prognostic biomarkers
• Combination Therapies: Rising interest in multi-target approaches

Emerging Investment Areas

With 324 terminated trials historically, the field is actively exploring new modalities. [Microbiome](/entities/microbiome)-based approaches represent an emerging area with growing trial activity. Senolytic therapies targeting cellular senescence are entering early-phase trials. Gene therapy vectors for [APP](/entities/app-protein) and related genes are under development, though clinical translation remains challenging.

Priority Research Gaps

Late-Stage Development Bottleneck

Only 6.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.

Recommended Priorities

Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints

Trial Design Innovation: Adaptive trials and platform protocols

Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure

Therapeutic Target Priorities

Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:

• amyloid: 395 trials - Well-established
• mitochondrial: 346 trials - Well-established
• genetic: 226 trials - Well-established
• tau: 118 trials - Well-established
• tauro: 118 trials - Well-established

Recent Investment Developments (2024-2025)

Approved Therapies

The Alzheimer's investment landscape has been transformed by the 2023-2024 approvals of disease-modifying therapies:

• [Lecanemab](/entities/lecanemab) (Leqembi, Biogen/Eisai): Full FDA approval in July 2023, CMS coverage decision expanded in 2024
• [Donanemab](/entities/donanemab) (Kisunla, Eli Lilly): FDA approved July 2024, first amyloid-targeting therapy with potential for limited treatment duration
• Other candidates: Gantenerumab (Roche) discontinued in 2022; Crenezumab (Roche) showed limited efficacy

Key Pipeline Updates (2025)

• RNL-441 (Lundbeck): Anti-amyloid antibody in Phase 3 for early AD
• AL-002 (Alector/GSK): TREM2 agonist advancing in Phase 2
• ACI-35 (ACI): Lipid-based tau vaccine in Phase 2
• Semorinemab (Roche): Anti-tau antibody showing promise in Phase 2
• Protollin (Prothelia): Novel immunotherapy with Phase 2 data expected 2025

Investment Themes

• Combination approaches: Amyloid removal + tau targeting + neuroinflammation modulation
• Early intervention: Trials in pre-symptomatic populations with biomarker confirmation
• Blood-based biomarkers: p-tau217, p-tau181 enabling wider screening
• Generic/biosimilar competition: Expected for approved antibodies by 2028-2030

Investment Outlook

Near-Term Opportunities (1-3 Years)

Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.

Medium-Term Opportunities (3-5 Years)

Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.

Long-Term Vision (5-10 Years)

Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Clinical Trials: Alzheimer's](/clinical-trials/alzheimers-disease)

External Links

• [Alzheimer's Association](https://www.alz.org/) - Leading voluntary health organization for Alzheimer's
• [ClinicalTrials.gov AD Studies](https://clinicaltrials.gov/search?cond=Alzheimer+Disease) - Current AD clinical trials
• [National Institute on Aging](https://www.nia.nih.gov/health/alzheimers) - NIH Alzheimer's research portal

See Also

• [Neurodegenerative Disease Research](/diseases/neurodegeneration)
• [Therapeutic Development](/therapeutics/therapeutic-development)
• [Clinical Trials](/clinical-trials/clinical-trials-index)
• [Biomarkers](/mechanisms/neurodegenerative-biomarkers)
• [Drug Discovery](/mechanisms/drug-discovery)

References

Unknown, ClinicalTrials.gov (n.d.)